Fed Circuit rejects Stanford DNA test appeal

The US Court of Appeals for the Federal Circuit yesterday, July 10, handed victory to researchers at the Chinese University of Hong Kong (CUHK) in a case involving a foetal testing patent.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circ. affirms Stanford genetics patent rejection

26 March 2021 The Federal Circuit has affirmed a Patent Trial and Appeal Board decision denying Stanford University a patent application for calculating parent genes.

Genetics

23andMe petitions Fed Circuit for en banc review

8 November 2019 DNA testing and analysis company 23andMe has asked the full US Court of Appeals for the Federal Circuit to review an earlier panel decision which held that one of its patents is invalid.

Americas

Federal Circuit vacates PTAB’s decision on foetal testing patent

28 June 2017 The US Court of Appeals for the Federal Circuit has vacated and remanded the Patent Trial and Appeal Board’s decision to invalidate a foetal testing patent.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Fed Circuit rejects Stanford DNA test appeal

More on this story

Editor's picks

Editor's picks

More features